LeonaBio, Inc.

NasdaqCM:LONA Stock Report

Market Cap: US$52.0m

LeonaBio Future Growth

Future criteria checks 0/6

LeonaBio's earnings are forecast to decline at 19.6% per annum while its annual revenue is expected to grow at 72.9% per year. EPS is expected to grow by 36.5% per annum.

Key information

-19.6%

Earnings growth rate

36.47%

EPS growth rate

Pharmaceuticals earnings growth11.3%
Revenue growth rate72.9%
Future return on equityn/a
Analyst coverage

Low

Last updated03 Mar 2026

Recent future growth updates

Recent updates

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Feb 16
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Nov 02
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

May 29
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Oct 17

Athira Pharma GAAP EPS of -$0.65

Aug 15

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Aug 09
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Jun 22

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

May 08
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Jan 11
We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Athira Pharma: What, Exactly, Did The CEO Do?

Jun 29

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

May 24
We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Feb 08
We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Dec 18
Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

Earnings and Revenue Growth Forecasts

NasdaqCM:LONA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-164-155N/A2
12/31/2027N/A-138-129N/A2
12/31/2026N/A-72-95N/A3
12/31/2025N/A-32-36N/A3
9/30/2025N/A-38-52-52N/A
6/30/2025N/A-60-71-71N/A
3/31/2025N/A-80-86-86N/A
12/31/2024N/A-97-97-97N/A
9/30/2024N/A-109-97-97N/A
6/30/2024N/A-113-98-98N/A
3/31/2024N/A-116-100-100N/A
12/31/2023N/A-118-101-101N/A
9/30/2023N/A-121-90-90N/A
6/30/2023N/A-108-88-88N/A
3/31/2023N/A-102-83-82N/A
12/31/2022N/A-96-74-72N/A
9/30/2022N/A-82-77-75N/A
6/30/2022N/A-77-66-64N/A
3/31/2022N/A-67-54-52N/A
12/31/2021N/A-55-45-43N/A
9/30/2021N/A-46-38-36N/A
6/30/2021N/A-39-37-35N/A
3/31/2021N/A-27-33-30N/A
12/31/2020N/A-20-26-24N/A
9/30/2020N/A-13-15-14N/A
6/30/2020N/A-6-6-6N/A
3/31/2020N/A-6-4-4N/A
12/31/2019N/A-5-4-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LONA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LONA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LONA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LONA is forecast to have no revenue next year.

High Growth Revenue: LONA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LONA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/04 03:28
End of Day Share Price 2026/03/03 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LeonaBio, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Eric SchmidtCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC